Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Nuclear Medicine and Molecular Imaging
Published in: Nuclear Medicine and Molecular Imaging 4/2019

01-08-2019 | Photodynamic Therapy | Perspective

Theranostics Based on Liposome: Looking Back and Forward

Authors: Wooseung Lee, Hyung-Jun Im

Published in: Nuclear Medicine and Molecular Imaging | Issue 4/2019

Login to get access

Abstract

Liposome is one of the oldest yet most successful nanomedicine platforms. Doxil®, PEGylated liposome loaded with doxorubicin (DOX), was approved by the FDA in 1995 for the treatment of AIDS-related Kaposi’s sarcoma, and it was the first approval for nanomedicine. Since then, liposome-based therapeutics were approved for the treatment of various diseases and many clinical trials are underway. The success of the liposome-based therapeutics was due to following factors: (1) ease of synthesis, (2) biocompatibility, (3) the ability to load both hydrophilic and hydrophobic agents, and (4) long circulation property after application of polyethylene glycol (PEG). Recently, more functionalities are introduced to liposome platform, which are (1) in vivo imaging probes for optical, magnetic resonance imaging (MRI), positron emission tomography (PET), and single-photon emission computed tomography (SPECT), (2) pH and temperature-sensitive lipid moiety, and (3) novel agents for photodynamic and photothermal therapies (PDT, PTT). These conventional and newly tested advantages make the liposome to be one of the most promising nanoplatforms for theranostics.
Literature
1.
2.
3.
Barenholz Y. Doxil(R)--the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160:117–34.CrossRefPubMed
4.
Adler-moore JP, Proffitt RT. Development, characterization, efficacy and mode of action of ambisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3:429–50.CrossRef
5.
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9.
6.
Gardikis K, Tsimplouli C, Dimas K, Micha-Screttas M, Demetzos C. New chimeric advanced drug delivery nano systems (chi-aDDnSs) as doxorubicin carriers. Int J Pharm. 2010;402:231–7.CrossRefPubMed
7.
Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19:1444–54.CrossRefPubMed
8.
Silverman JA, Deitcher SR. Marqibo(R) (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine. Cancer Chemother Pharmacol. 2013;71:555–64.CrossRefPubMed
9.
Merhav H, Mieles L. Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients. Transplant Proc. 1997;29:2670–4.CrossRefPubMed
10.
Bovier PA. Epaxal: a virosomal vaccine to prevent hepatitis A infection. Expert Rev Vaccines. 2008;7:1141–50.CrossRefPubMed
11.
Jonas JB. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol. 2002;133:857–9.CrossRefPubMed
12.
Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9:12.CrossRefPubMedCentral
13.
Pattni BS, Chupin VV, Torchilin VP. New developments in liposomal drug delivery. Chem Rev. 2015;115:10938–66.CrossRefPubMed
14.
Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope. J Mol Biol. 1964;8:660–8.CrossRefPubMed
15.
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1:297–315.CrossRefPubMedPubMedCentral
16.
Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994;54:987–92.PubMed
17.
18.
Im HJ, England CG, Feng L, et al. Accelerated blood clearance phenomenon reduces the passive targeting of PEGylated nanoparticles in peripheral arterial disease. ACS Appl Mater Interfaces. 2016;8:17955–63.CrossRefPubMedPubMedCentral
19.
Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005;105:305–17.CrossRefPubMed
20.
Xu H, Ye F, Hu M, et al. Influence of phospholipid types and animal models on the accelerated blood clearance phenomenon of PEGylated liposomes upon repeated injection. Drug Deliv. 2015;22:598–607.CrossRefPubMed
21.
Borresen B, Henriksen JR, Clergeaud G, et al. Theranostic imaging may vaccinate against the therapeutic benefit of long circulating PEGylated liposomes and change cargo pharmacokinetics. ACS Nano. 2018;12:11386–98.CrossRefPubMed
22.
Ishihara T, Maeda T, Sakamoto H, et al. Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules. 2010;11:2700–6.CrossRefPubMed
23.
Zhang Q, Deng C, Fu Y, Sun X, Gong T, Zhang Z. Repeated administration of hyaluronic acid coated liposomes with improved pharmacokinetics and reduced immune response. Mol Pharm. 2016;13:1800–8.CrossRefPubMed
24.
Li Y, Liu R, Shi Y, Zhang Z, Zhang X. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon. Theranostics. 2015;5:583–96.CrossRefPubMedPubMedCentral
25.
Deissler V, Ruger R, Frank W, Fahr A, Kaiser WA, Hilger I. Fluorescent liposomes as contrast agents for in vivo optical imaging of edemas in mice. Small. 2008;4:1240–6.CrossRefPubMed
26.
Mukthavaram R, Wrasidlo W, Hall D, Kesari S, Makale M. Assembly and targeting of liposomal nanoparticles encapsulating quantum dots. Bioconjug Chem. 2011;22:1638–44.CrossRefPubMedPubMedCentral
27.
Tagami T, Foltz WD, Ernsting MJ, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 2011;32:6570–8.CrossRefPubMed
28.
Mikhaylov G, Mikac U, Magaeva AA, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011;6:594.CrossRefPubMed
29.
Petersen AL, Henriksen JR, Binderup T, et al. In vivo evaluation of PEGylated (6)(4)Cu-liposomes with theranostic and radiotherapeutic potential using micro PET/CT. Eur J Nucl Med Mol Imaging. 2016;43:941–52.CrossRefPubMed
30.
Lee H, Gaddy D, Ventura M, et al. Companion diagnostic (64)Cu-liposome positron emission tomography enables characterization of drug delivery to tumors and predicts response to cancer nanomedicines. Theranostics. 2018;8:2300–12.CrossRefPubMedPubMedCentral
31.
Seo JW, Zhang H, Kukis DL, Meares CF, Ferrara KW. A novel method to label preformed liposomes with 64Cu for positron emission tomography (PET) imaging. Bioconjug Chem. 2008;19:2577–84.CrossRefPubMedPubMedCentral
32.
Phillips WT, Rudolph AS, Goins B, Timmons JH, Klipper R, Blumhardt R. A simple method for producing a technetium-99m-labeled liposome which is stable in vivo. Int J Rad Appl Instrum B. 1992;19:539–47.CrossRefPubMed
33.
Feng L, Cheng L, Dong Z, et al. Theranostic liposomes with hypoxia-activated prodrug to effectively destruct hypoxic tumors post-photodynamic therapy. ACS Nano. 2017;11:927–37.CrossRefPubMed
34.
Ma M, Lei M, Tan X, Tan F, Li N. Theranostic liposomes containing conjugated polymer dots and doxorubicin for bio-imaging and targeted therapeutic delivery. RSC Adv. 2016;6:1945–57.CrossRef
35.
Zhang K, Zhang Y, Meng X, et al. Light-triggered theranostic liposomes for tumor diagnosis and combined photodynamic and hypoxia-activated prodrug therapy. Biomaterials. 2018;185:301–9.CrossRefPubMed
36.
Rengan AK, Bukhari AB, Pradhan A, et al. In vivo analysis of biodegradable liposome gold nanoparticles as efficient agents for photothermal therapy of Cancer. Nano Lett. 2015;15:842–8.CrossRefPubMed
37.
Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–98.PubMedPubMedCentral
38.
Demel RA, De Kruyff B. The function of sterols in membranes. Biochim Biophys Acta. 1976;457:109–32.CrossRefPubMed
39.
Yu L, Dong A, Guo R, Yang M, Deng L, Zhang J. DOX/ICG Coencapsulated liposome-coated thermosensitive nanogels for nir-triggered simultaneous drug release and photothermal effect. ACS Biomater Sci Eng. 2018;4:2424–34.CrossRefPubMed
40.
Lai MZ, Duzgunes N, Szoka FC. Effects of replacement of the hydroxyl group of cholesterol and tocopherol on the thermotropic behavior of phospholipid membranes. Biochemistry. 1985;24:1646–53.CrossRefPubMed
41.
Webb MS, Wheeler JJ, Bally MB, Mayer LD. The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery. Biochim Biophys Acta. 1995;1238:147–55.CrossRefPubMed
42.
Nayar R, Schroit AJ. Generation of pH-sensitive liposomes: use of large unilamellar vesicles containing N-succinyldioleoylphosphatidylethanolamine. Biochemistry. 1985;24:5967–71.CrossRefPubMed
43.
Zhao Y, Ren W, Zhong T, et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release. 2016;222:56–66.CrossRefPubMed
44.
Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1:16014.CrossRef
Metadata
Title
Theranostics Based on Liposome: Looking Back and Forward
Authors
Wooseung Lee
Hyung-Jun Im
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Nuclear Medicine and Molecular Imaging / Issue 4/2019
Print ISSN: 1869-3474
Electronic ISSN: 1869-3482
DOI
https://doi.org/10.1007/s13139-019-00603-z

Other articles of this Issue 4/2019

Nuclear Medicine and Molecular Imaging 4/2019 Go to the issue

Original Article

The Correlation Between Tenosynovitis Pattern on Two-Phase Bone Scintigraphy and Clinical Manifestation in Patients with Suspected Rheumatoid Arthritis

Review

Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy

Interesting Image

18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma

Original Article

Value of the Filtration Fraction Assessed by Dynamic 99mTc-Diethylenetriaminepentaacetic Acid Renal Scintigraphy After Angiotensin-Converting Enzyme Inhibition for the Diagnosis of Renovascular Hypertension

Original Article

Treatment Response Assessment of Skeletal Metastases in Prostate Cancer with 18F-NaF PET/CT

Original Article

Minimum Standardized Uptake Value from Quantitative Bone Single-Photon Emission Computed Tomography/Computed Tomography for Evaluation of Femoral Head Viability in Patients with Femoral Neck Fracture